Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone
1-(beta-D-ribofuranosyl)nicotinamide + a hydroquinone
-
Substrates: -
Products: -
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone
1-(beta-D-ribofuranosyl)nicotinamide + a quinol
Substrates: -
Products: -
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + co-enzyme Q
1-(beta-D-ribofuranosyl)nicotinamide + reduced co-enzyme Q
-
Substrates: natural substrate nicotinamide riboside, NRH
Products: -
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + menadione
1-(beta-D-ribofuranosyl)nicotinamide + menadiol
1-(carbamoylmethyl)dihydronicotinamide + 3-hydroxy-1-methylindoline-5,6-dione
1-(carbamoylmethyl)nicotinamide + 3-hydroxy-1-methylindoline-5,6-diol
-
Substrates: 3-hydroxy-1-methylindoline-5,6-dione i.e. adrenochrome
Products: -
?
1-benzyl-1,4-dihydronicotinamide + estradiol-3,4-quinone
1-benzyl-3-carbamoylpyridinium + estrone-3,4-quinone
-
Substrates: -
Products: -
r
1-carbamoylmethyl-3-carbamoyl-1,4-dihydropyrimidine + menadione
1-carbamoylmethyl-3-carbamoylpyrimidine + menadiol
Substrates: -
Products: -
?
17beta-17-hydroxyestr-1(10)-ene-3,4-dione + N-benzyldihydronicotinamide
17beta-estra-1(10),2,4-triene-3,4,17-triol + N-benzylnicotinamide
-
Substrates: ping-pong mechanism, NQO2 is faster in reducing estrogen quinones than its homologue NQO1
Products: -
?
2,6-dichloroindophenol + dihydronicotinamide riboside
?
Substrates: -
Products: -
?
2,6-dichloroindophenol + dihydronicotinamide riboside
? + nicotinamide riboside
2H-dibenzo[b,f]azepin-2-one + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
5-(aziridin-1-yl)-2,4-dinitrobenzamide + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
5-(aziridin-1-yl)-2,4-dinitrobenzamide + menadiol
? + reduced menadiol
-
Substrates: -
Products: -
?
amodiaquine quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
benzo(a)pyrene-3,6-quinone + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
desethylamodiaquine quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
diclofenac-1',4'-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
diclofenac-2,5-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
dihydrobenzylnicotinamide + menadione
?
-
Substrates: -
Products: -
?
dihydronicotinamide riboside + 2,6-dichlorophenolindophenol
nicotinamide riboside + reduced 2,6-dichlorophenolindophenol
-
Substrates: -
Products: -
?
dihydronicotinamide riboside + 3-(4,5-dimethylthiazaol-2-yl)-2,5-diphenyltetrazolium
nicotinamide riboside + ?
-
Substrates: -
Products: -
?
dihydronicotinamide riboside + CB 1954
nicotinamide riboside + ?
-
Substrates: -
Products: -
?
dihydronicotinamide riboside + menadione
ribosyl nicotinamide + menadiol
-
Substrates: -
Products: -
?
dihydronicotinamide riboside + menadione/3-(4,5-dimethylthiazaol-2-yl)-2,5-diphenyltetrazolium
nicotinamide riboside + ?
-
Substrates: -
Products: -
?
dihydronicotinamide riboside + methyl red
nicotinamide riboside + ?
-
Substrates: -
Products: -
?
estrone-3,4-quinone + N-benzyldihydronicotinamide
estrone-3,4-quinol + N-benzylnicotinamide
-
Substrates: ping-pong mechanism, NQO2 is faster in reducing estrogen quinones than its homologue NQO1
Products: -
?
mefenamic acid-1',4'-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
mefenamic acid-2,5-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
menadione + 1-(2-hydroxyethyl)dihydronicotinamide
?
Substrates: -
Products: -
?
menadione + 1-benzyl-1,4-dihydronicotinamide
?
Substrates: -
Products: -
?
menadione + dihydrobenzylnicotinamide
?
menadione + dihydronicotinamide riboside
menadiol + nicotinamide riboside
Substrates: -
Products: -
?
mitomycin C + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
N-acetyl-p-benzoquinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + 2,6-dichlorophenolindophenol
N-benzylnicotamide + reduced 2,6-dichlorophenolindophenol
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + 2,6-dichlorophenolindophenol
N-benzylnicotinamide + reduced 2,6-dichlorophenolindophenol
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + a quinone
N-benzylnicotinamide + a hydroquinone
-
Substrates: synthetic substrate
Products: -
?
N-benzyldihydronicotinamide + coenzyme Q0
?
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + coenzyme Q0
N-benzylnicotinamide + ?
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + coenzyme Q1
N-benzylnicotinamide + ?
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + menadione
?
N-benzyldihydronicotinamide + menadione
N-benzylnicotamide + menadiol
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + menadione
N-benzylnicotinamide + menadiol
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + oxidized coenzyme Q0
N-benzylnicotinamide + reduced coenzyme Q20
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + oxidized coenzyme Q1
N-benzylnicointamide + reduced coenzyme Q1
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + oxidized coenzyme Q2
N-benzylnicotinamide + reduced coenzyme Q2
-
Substrates: -
Products: -
?
N-benzylnicotinamide + menadiol
?
-
Substrates: -
Products: -
?
N-methyldihydronicotinamide + 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
N-methylnicotinamide + ?
-
Substrates: -
Products: -
?
N-methyldihydronicotinamide + 3-hydroxy-1-methylindoline-5,6-dione
N-methylnicotinamide + 3-hydroxy-1-methylindoline-5,6-diol
-
Substrates: 3-hydroxy-1-methylindoline-5,6-dione i.e. adrenochrome. When NADH is used as the electron donor, quinone reductase 2 possesses no activity for the reduction of adrenochrome
Products: -
?
N-methyldihydronicotinamide + menadione
?
N-methyldihydronicotinamide + menadione
N-methylnicotinamide + menadiol
N-ribosylnicotinamide + menadiol
?
-
Substrates: N-ribosylnicotinamide is a poor substrate
Products: -
?
NADH + 2,6-dichlorophenolindophenol
?
-
Substrates: -
Products: -
r
nicotinamide riboside + menadiol
dihydronicotinamide riboside + menadione
-
Substrates: -
Products: -
?
nicotinamide riboside + reduced 2,6-dichlorophenolindophenol
dihydronicotinamide riboside + 2,6-dichlorophenolindophenol
-
Substrates: -
Products: -
?
nicotinamide riboside + reduced coenzyme Q0
dihydronicotinamide riboside + coenzyme Q0
-
Substrates: -
Products: -
?
nicotinamide riboside + reduced coenzyme Q1
dihydronicotinamide riboside + coenzyme Q1
-
Substrates: -
Products: -
?
nicotinamide riboside + reduced coenzyme Q2
dihydronicotinamide riboside + coenzyme Q2
-
Substrates: -
Products: -
?
reduced N-methyldihydronicotinamide + menadione
? + menadiol
-
Substrates: -
Products: -
?
reduced N1-(benzyl)-nicotinamide + menadione
N1-(benzyl)-nicotinamide + menadiol
-
Substrates: -
Products: -
?
reduced N1-(methyl)-nicotinamide + menadione
N1-(methyl)-nicotinamide + reduced menadiol
-
Substrates: -
Products: -
?
reduced N1-(n-propyl)-nicotinamide + menadione
N1-(n-propyl)-nicotinamide + menadiol
-
Substrates: -
Products: -
?
tetrahydrofolate + menadiol
?
-
Substrates: -
Products: -
?
additional information
?
-
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + menadione
1-(beta-D-ribofuranosyl)nicotinamide + menadiol
-
Substrates: -
Products: -
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + menadione
1-(beta-D-ribofuranosyl)nicotinamide + menadiol
-
Substrates: natural substrate nicotinamide riboside, NRH
Products: -
?
2,6-dichloroindophenol + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
2,6-dichloroindophenol + dihydronicotinamide riboside
? + nicotinamide riboside
Substrates: -
Products: -
?
menadione + dihydrobenzylnicotinamide
?
-
Substrates: -
Products: -
?
menadione + dihydrobenzylnicotinamide
?
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + menadione
?
-
Substrates: -
Products: -
?
N-benzyldihydronicotinamide + menadione
?
-
Substrates: -
Products: -
?
N-methyldihydronicotinamide + menadione
?
-
Substrates: -
Products: -
?
N-methyldihydronicotinamide + menadione
?
Substrates: -
Products: -
?
N-methyldihydronicotinamide + menadione
N-methylnicotinamide + menadiol
-
Substrates: -
Products: -
?
N-methyldihydronicotinamide + menadione
N-methylnicotinamide + menadiol
Substrates: -
Products: -
?
additional information
?
-
-
Substrates: no activity with NADH, NADPH, NMNH, reduced 3-acetylpyridine adenine dinucleotide, xanthine or hypoxanthine. No activity with 1,4-benzoquinone and potassium ferricyanide
Products: -
?
additional information
?
-
-
Substrates: enzyme exhibits melatonin-binding activity
Products: -
?
additional information
?
-
Substrates: high QR2 activity might make individuals more susceptible to ParkinsonĀs disease. By inhibiting QR2, it seems that anti-malarial compounds such as quinacrine favour the red blood cell oxidative stress leading to the death of the parasite
Products: -
?
additional information
?
-
Substrates: knockdown K562 cells exhibit increased antioxidant and detoxification enzyme expression and reduced proliferation rates
Products: -
?
additional information
?
-
-
Substrates: the expression of the NQO2 gene is induced in response to 2,3,7,8-tetrachlorodibenzo-p-dioxin
Products: -
?
additional information
?
-
Substrates: enzyme cannot use NADH or NADPH as reducing agent
Products: -
?
additional information
?
-
-
Substrates: no activity with one-electron acceptors such as potassium ferricyanide
Products: -
?
additional information
?
-
-
Substrates: the D allele in the promoter is associated with higher NQO2 activity and increases levels of ROS in the presence of dopamine, which would then increase susceptibility to Parkinson's disease
Products: -
?
additional information
?
-
-
Substrates: NQO2 catalyzes the reduction of electrophilic estrogen quinones and thereby may act as a detoxification enzyme
Products: -
?
additional information
?
-
-
Substrates: the enzyme does not accept conventional phosphorylated nicotinamides as hydride donors
Products: -
?
additional information
?
-
-
Substrates: NQO2 can function as a nitroreductase in activating the antitumor drug 5-aziridinyl-2,4-dinitrobenzamide
Products: -
?
additional information
?
-
-
Substrates: the enzyme catalyzes the reduction of quinones, such as menadione and co-enzyme Q
Products: -
?
additional information
?
-
-
Substrates: QR2 produces free radicals with pro-drug CB1954, i.e. 5-(aziridin-1-yl)-2,4-dinitrobenzamide. The anti-cancer pro-drug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) is transformed into a potent cytotoxic drug upon reduction of its 4-nitro group to a 4-hydroxylamine by quinone reductases or nitroreductase
Products: -
?
additional information
?
-
-
Substrates: quinone reductase 2 (QR2) is implicated in the reduction of quinone in the presence of natural derivatives of NADH such as N-ribosyldihydronicotinamide. QR2 does not recognize NADH or NADPH as co-substrates, unlike quinone reductase 1 (QR1)
Products: -
?
additional information
?
-
Substrates: no substrate: 5-hydroxydiclofenac quinone imine
Products: -
-
additional information
?
-
-
Substrates: no substrate: 5-hydroxydiclofenac quinone imine
Products: -
-
additional information
?
-
-
Substrates: enzyme exhibits melatonin-binding activity
Products: -
?
additional information
?
-
-
Substrates: by deleting QR2 it seems that mice become increasingly susceptible to polycyclic aromatic hydrocarbon-induced skin carcinogenesis
Products: -
?
additional information
?
-
-
Substrates: organs of mice deleted for NQO2 are depleted of MT3 binding sites. NQO2 is part of the melatonin receptor MT3 binding sites
Products: -
?
additional information
?
-
-
Substrates: quinone reductase 2 is a target of resveratrol in vascular smooth muscle cells. Resveratrol reduces quinone reductase protein levels and suppresses quinone reductase 2 mRNA expression in cultured vascular smooth muscle cell. The inhibition of vascular smooth muscle cell proliferation by resveratrol is effected via the negative regulation of quinone reductase 2. Quinone reductase 2 may be the main target for resveratrol and may be used to mediate the potential therapeutic role of resveratrol in atherosclerosis and restenosis after injury
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(E)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylaldehyde
-
-
(E)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol
-
-
(Z)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)-acrylamide
-
-
(Z)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylonitrile
-
-
(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylaldehyde
-
-
(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
-
-
(Z)-5-(3-hydroxy-2-(4-hydroxyphenyl)prop-1-en-1-yl)benzene-1,3-diol
-
-
1,1'-(1E)-but-1-ene-1,2-diylbis(3,5-dimethoxybenzene)
-
-
1,2-dimethoxy-4-[(1E)-2-(4-methoxyphenyl)prop-1-en-1-yl]benzene
-
-
1,2-dimethoxy-4-[(E)-2-(3-methoxyphenyl)ethenyl]benzene
-
-
1,2-dimethoxy-4-{(1Z)-3,3,3-trifluoro-2-[3-(trifluoromethyl)phenyl]prop-1-en-1-yl}benzene
-
-
1,3-dimethoxy-5-[(1E)-2-(4-methoxyphenyl)prop-1-en-1-yl]benzene
-
-
1,3-dimethoxy-5-[(1Z)-3,3,3-trifluoro-1-(4-methoxyphenyl)prop-1-en-2-yl]benzene
-
-
1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene
-
-
1,4-dimethylphenanthrene
-
0.00001 mM, 15% inhibition of the reaction with N1-(n-propyl)-nicotinamide
1,4-dimethylquinolin-2(1H)-one
-
-
1-[(E)-2-(4-fluorophenyl)ethenyl]-3,5-dimethoxybenzene
-
-
12-methylbenz[a]anthracene
-
0.00001 mM, 51% inhibition of the reaction with N1-(n-propyl)-nicotinamide
2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-yl)ethylamine
-
IC50: 0.00087 mM
2-hydroxyestradiol
-
0.01 mM, 17% inhibition
2-iodo-5-methoxycarbonylamino-N-acetyltryptamine
-
-
2-iodo-melatonin
-
IC50: 0.016 mM
2-methoxy-6-((2-(6-methoxy-2-methylquinolin-4-yl)hydrazono)methyl)phenol
-
-
2-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]naphthalene
-
-
2-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]naphthalene
-
-
3-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
-
-
3-{[4-(dihydroxyamino)phenoxy]methyl}-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione
-
-
4',5,7-trihydroxyflavone
-
0.01 mM, 61% inhibition
4-(5-phenyl-1,3-oxazol-2-yl)benzene-1-carboximidamide
-
inhibits the growth of Plasmodium falciparum with an IC50 value of 0.3 microM
-
4-(5-phenylfuran-2-yl)benzene-1-carboximidamide
-
-
4-(5-phenylthiophen-2-yl)benzene-1-carboximidamide
-
-
4-hydroxyestradiol
-
0.01 mM, 18% inhibition
4-hydroxyestrone
-
0.01 mM, 22% inhibition
4-[(1E)-1-(3,5-dimethoxyphenyl)prop-1-en-2-yl]-1,2-dimethoxybenzene
-
-
4-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-N,N-dimethylaniline
-
-
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-1,2-dimethoxybenzene
-
-
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol
-
-
4-[(E)-2-(3-fluorophenyl)ethenyl]benzene-1,2-diol
-
-
4-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,2-diol
-
-
4-[(E)-2-(4-methoxyphenyl)ethenyl]benzene-1,2-diol
-
-
4-[(Z)-(1H-imidazol-4-yl)diazenyl]-6-methoxy-2-methylquinoline
-
-
4-[(Z)-(4-fluorophenyl)diazenyl]-6-methoxy-2-methylquinoline
-
-
4-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]benzoic acid
-
-
4-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
-
-
4-[(Z)-benzyldiazenyl]-6-methoxy-2-methylquinoline
-
-
4-[(Z)-[(1H-imidazol-4-yl)methyl]diazenyl]-6-methoxy-2-methylquinoline
-
-
4-{(1E)-1-[4-(trifluoromethyl)phenyl]prop-1-en-2-yl}phenol
-
-
4-{(E)-2-[3-(trifluoromethyl)phenyl]ethenyl}benzene-1,2-diol
-
-
5,6,8-trimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
5,6,8-trimethoxy-4-methylquinolin-2(1H)-one
-
-
5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
5,8-dimethoxy-4-methylquinolin-2(1H)-one
-
-
5-(2-(dimethylamino)ethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
-
5-(2-(dimethylamino)ethylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
-
5-(2-(dimethylamino)ethylamino)-8-fluoro-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
-
5-(3-hydroxypropylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(3-hydroxypropylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(3-hydroxypropylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(4-methoxyphenylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(isopentylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(phenethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-amino-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-hydroxyflavone
-
IC50: 340 nM
5-methoxy-carbonylamino-N-acetyltryptamine
-
IC50: 0.295 mM
5-methoxycarbonylamino-N-acetyltryptamine
5-[(1E)-1-(4-hydroxyphenyl)prop-1-en-2-yl]benzene-1,3-diol
-
-
5-[(1E)-2-(3,4-dimethoxyphenyl)prop-1-en-1-yl]benzene-1,3-diol
-
-
5-[(1E)-2-(4-hydroxyphenyl)prop-1-en-1-yl]benzene-1,3-diol
-
-
5-[(1E)-2-(4-methoxyphenyl)prop-1-en-1-yl]benzene-1,3-diol
-
-
5-[(4-aminobutyl)amino]-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[(4-aminobutyl)amino]-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[(8-aminooctyl)amino]-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]benzene-1,3-diol
-
-
5-[butyl(methyl)amino]-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[[4-(diethylamino)butyl]amino]-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-7,10-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-7-hydroxy-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-7-hydroxy-8,9-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
most potent inhibitor of NQO2
5-[[4-(diethylamino)butyl]amino]-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-8-methoxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-8-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-9-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-1-ethyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[6-(diethylamino)hexyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[6-(dimethylamino)hexyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-{(1E)-1-[4-(dimethylamino)phenyl]but-1-en-2-yl}benzene-1,3-diol
-
-
5-{[2-(dimethylamino)ethyl]amino}-1,2-dimethyl-3-(phenoxymethyl)-1H-indole-4,7-dione
-
-
5-{[2-(dimethylamino)ethyl]amino}-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-{[2-(dimethylamino)ethyl]amino}-1-methyl-2-phenyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-{[2-(dimethylamino)ethyl]amino}-1-methyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-{[3-(dimethylamino)propyl]amino}-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
6,7,8-trimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
6,7,8-trimethoxy-4-methylquinolin-2(1H)-one
-
-
6,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
6,8-dimethoxy-4-methylquinolin-2(1H)-one
-
-
6,9-dimethyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
-
-
6-methoxy-2-methyl-4-[(Z)-(4-nitrophenyl)diazenyl]quinoline
-
-
6-methoxy-2-methyl-4-[(Z)-(5-nitrofuran-2-yl)diazenyl]quinoline
-
-
6-methoxy-2-methyl-4-[(Z)-(pyridin-3-yl)diazenyl]quinoline
-
-
6-methoxy-9-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
-
-
6-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
-
-
7,12-dimethylbenz[a]anthracene
-
0.00001 mM, 51% inhibition of the reaction with N1-(n-propyl)-nicotinamide
7,8-dihydroxyflavone
-
0.01 mM, 7% inhibition
7,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
7,8-dimethoxy-4-methylquinolin-2(1H)-one
-
-
7-methylbenz[a]anthracene
-
0.00001 mM, 66% inhibition of the reaction with N1-(n-propyl)-nicotinamide
8-bromo-5-[(3-methylbutyl)amino]-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
8-methoxy-1,4-dimethylquinolin-2(1H)-one
-
-
8-methoxy-4-methylquinolin-2(1H)-one
-
-
8-methoxy-5-(phenethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
9,10-dimethylanthracene
-